– IND filing expected in mid-2025 – LEXINGTON, Mass. , Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its
Categories
Recent Posts
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
- Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
- Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)